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Background: Accurate interpretation of rare genetic variants is a challenge for clinical translation. Updates in
recommendations for rare variant classification require the reanalysis and reclassification. We aim to per-
form an exhaustive re-analysis of rare variants associated with inherited arrhythmogenic syndromes, which
were classified ten years ago, to determine whether their classification aligns with current standards and
research findings.
Methods: In 2010, the rare variants identified through genetic analysis were classified following recommen-
dations available at that time. Nowadays, the same variants have been reclassified following current Ameri-
can College of Medical Genetics and Genomics recommendations.
Findings: Our cohort included 104 cases diagnosed with inherited arrhythmogenic syndromes and 17 post-
mortem cases in which inherited arrhythmogenic syndromes was cause of death. 71.87% of variants change
their classification. While 65.62% of variants were classified as likely pathogenic in 2010, after reanalysis,
only 17.96% remain as likely pathogenic. In 2010, 18.75% of variants were classified as uncertain role but
nowadays 60.15% of variants are classified of unknown significance.
Interpretation: Reclassification occurred in more than 70% of rare variants associated with inherited arrhyth-
mogenic syndromes. Our results support the periodical reclassification and personalized clinical translation
of rare variants to improve diagnosis and adjust treatment.
Funding: Obra Social "La Caixa Foundation" (ID 100010434, LCF/PR/GN16/50290001 and LCF/PR/GN19/
50320002), Fondo Investigacion Sanitaria (FIS PI16/01203 and FIS, PI17/01690), Sociedad Espa~nola de Cardio-
logía, and “Fundacio Privada Daniel Bravo Andreu”.
© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)TaggedEndTaggedEndTaggedPKeywords:
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TaggedPAdvances in gene sequencing technology have made genetic
testing in clinical diagnosis more accessible by increasing the num-
ber of analysed genes, decreasing costs, and reducing the amount of
time required for analysis [1]. For an adequate translation of genetic
data to clinical practice, and in order to manage the inherited condi-
tions, it is critical to perform an appropriate interpretation of the
genetic variant [2]. Sudden death may be the first manifestation of
Research in context
Evidence before this study
The American College of Medical Genetics and Genomics
(ACMG) current recommendations include guidelines for
obtaining an accurate assessment of rare variants. However,
there is a lack of available data for each rare variant, and many
remain of uncertain significance. Therefore, many of the fami-
lies affected with inherited arrhythmic syndrome remain with
an inconclusive genetic diagnosis, which is not helpful in clini-
cal decision-making. Accurate interpretation of rare genetic
variants is a challenge for clinical translation. Updates in rec-
ommendations for rare variant classification require the reanal-
ysis and reclassification. An exhaustive review of the literature
concerning each variant was performed through December
2019. Data was collected from: HGMD (www.hgmd.org), Clin-
Var (www.ncbi.nlm.nih.gov/clinvar/intro/), the National Center
for Biotechnology Information SNP database (www.ncbi.nlm.
nih.gov/SNP), Index Copernicus (en.indexcopernicus.com),
Google Scholar (scholar.google.es), Springer Link (link.springer.
com), Science Direct (www.sciencedirect.com), Excerpta
Medica Database (www.elsevier.com/solutions/embase-bio
medical-research), and the IEEE Xplore Digital Library (ieeex-
plore.ieee.org/Xplore/home.jsp). All genetic variants included
in our study were compared to data from Exome Variant Server
(EVS; evs.gs.washington.edu/EVS), and Genome Aggregation
Database (gnomAD gnomad.broadinstitute.org/).
Added value of this study
Establishing a definite pathogenicity of rare genetic variants
helps for clinical diagnosis of inherited arrhythmogenic syn-
dromes but also helps to adopt therapeutic measures for pre-
vention of sudden death. We have performed an accurate
genetic reinterpretation of variants classified 10 years ago.
Reclassification occurred in more than 70% of rare variants
associated with inherited arrhythmogenic syndromes. These
changes may influence clinical decisions adopted 10 years ago.
Implications of all the available evidence
Currently, classification of a genetic variant follows guidelines
published in 2015 by ACMG/AMP. These recommendations are
based on available data concerning the variant at the moment
of classification. Data available 10 years ago is not the same as
now. Therefore, reclassification and reinterpretation of a vari-
ant should be updated periodically to improve diagnosis and
adjust treatment despite no concrete timeframe for this being
established. In the light of our results, we propose that rare var-
iants associated with inherited arrhythmogenic syndromes
should be reanalysed within five years if already classified fol-
lowing ACMG recommendations, since this seems to be ade-
quate to manage the rapid obsolescence of genetic data
interpretations. In addition, our results support further urgent
reanalysis of each IAS rare variant if they were not classified
originally following ACMG recommendations.
TaggedEnd2 O. Campuzano et al. / EBioMedicine 54 (2020) 102732TaggedEndTaggedP n inherited arrhythmic syndrome (IAS), thus early identification
with genetic technology may help adopt preventive measures and
reduce the risk of lethal episodes in family members. Genetic analy-
sis may also be determinant in identifying causality in sudden death
deemed inconclusive after a comprehensive autopsy. For these rea-
sons current guidelines recommend genetic analysis in diagnosed
patients and relatives who may be at risk, despite remaining asymp-
tomatic [3]. TaggedEndTaggedP he American College of Medical Genetics and Genomics (ACMG)
current recommendations include guidelines for obtaining an accu-
rate assessment of rare variants [4]. However, there is a lack of avail-
able data for each rare variant, and many remain of uncertain
significance. Therefore, many of the families affected with IAS remain
with an inconclusive genetic diagnosis, which is not helpful in clinical
decision-making [5]. Rare variants classified as inconclusive are dis-
regarded, and only clinical and family history are referenced in deter-
mining risk-assessment and clinical management [4].TaggedEnd
TaggedPClinical and functional data on rare IAS variants published in the
last ten years has helped clarify their roles and improved their classifi-
cation. Continuous reclassification is recommended to update their
roles before clinical translation. Such re-evaluation may serve to
improve psychological outcomes and risk stratification while promot-
ing personalized management [6, 7]. Only a few reports have
addressed this idea in recent years [810]. In the present study, we
describe the reclassification of rare IAS variants reported ten years ago
by our laboratory to update their roles following current guidelines.TaggedEnd
TaggedH12. Materials and methods TaggedEnd
TaggedH2 .1. Samples TaggedEnd
TaggedP his retrospective study reanalysed rare IAS variants classified in
our laboratory ten years ago (during the year 2010). Rare variants
were originally classified following recommendations available in
2010 as pathogenic (P), likely pathogenic (LP), variant of unknown sig-
nificance (VUS), or as likely benign (LB) [11]. Variants classified as
Benign in 2010 were not reanalysed due to global frequencies higher
than 1%, and already identified ten years ago as common variants. All
rare variants were identified in two groups: samples from patients
with a definite clinical diagnosis of IAS or post-mortem samples with-
out a conclusive cause of death but with suspected IAS. Genetic analy-
sis was approved by the ethics committee of Hospital Josep Trueta
(Girona, Spain) following the Helsinki II declaration. Both clinical and
genetic data concerning all patients were kept confidential. Written
informed consent was obtained from all patients included in the study.
In post-mortem cases, a family member authorized the study or judge/
legal authority included molecular autopsy as part of legal process.TaggedEnd
TaggedH2 .2. Genetic analysis TaggedEnd
TaggedPGenomic DNA was extracted with Chemagic MSM I from whole
blood (Chemagic human blood) or saliva (Chemagic Oragene Saliva).
Concentration was determined along with purity using a Nano-
Drop1000 spectrophotometer (Thermo scientific). Genomic DNA was
amplified by polymerase chain reaction (PCR) using intronic primers
for each exon of all the genes analysed. The PCR product was purified
by ExoSAP-IT (USB Corporation, Cleveland, OH, USA) and directly
sequenced by dideoxy chain-termination method in an ABI Prism Big
Dye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems,
USA). Sequencing was processed in a 3130XL Genetic Analyzer
(Applied Biosystems) and analysed by SeqScape Software v2.5 (Life
Technologies). TaggedEnd
TaggedP he genes associated with each IAS subtype were analysed follow-
ing the prevailing recommendations in 2010 [11]. Genetic analysis for
arrhythmogenic cardiomyopathy (ACM) included PKP2, DSP, DSC2,
DSG2, DES, JUP, and TGFB3; analysis for Brugada syndrome (BrS)
included SCN5A; analysis for catecholaminergic polymorphic ventric-
ular tachycardia (CPVT) included RYR2 and CASQ2; analysis for dilated
cardiomyopathy (DCM) included LMNA; analysis for hypertrophic
cardiomyopathy (HCM) included MYH7, MYBPC3, TNNT2, and TNNI3;
analysis for long QT Syndrome (LQTS) included KCNQ1, KCNH2, and
SCN5A; and finally, analysis for sick sinus syndrome (SSS) included
SCN5A and HCN4. The genes analysed in post-mortem cases were
SCN5A, KCNQ1, KCNH2, KCNE1, KCNE2, KCNE3, RYR2, and CASQ2. All
TaggedEndO. Campuzano et al. / EBioMedicine 54 (2020) 102732 3TaggedEndTaggedPoriginal sequences obtained in 2010 were comprehensively reana-
lysed with updated software (SeqScape v2.7, Applied Biosystems) to
identify any alteration not identified at the time of report. TaggedEnd
TaggedH2 .3. DataTaggedEnd
TaggedPAn exhaustive review of the literature concerning each variant
was performed through December 2019. Data was collected from:
HGMD (www.hgmd.org), ClinVar (www.ncbi.nlm.nih.gov/clinvar/
intro/), the National Center for Biotechnology Information SNP data-
base (www.ncbi.nlm.nih.gov/SNP), Index Copernicus (en.indexcoper-
nicus.com), Google Scholar (scholar.google.es), Springer Link (link.
springer.com), Science Direct (www.sciencedirect.com), Excerpta
Medica Database (www.elsevier.com/solutions/embase-biomedical-
research), and the IEEE Xplore Digital Library (ieeexplore.ieee.org/
Xplore/home.jsp). All genetic variants included in our study were
compared to data from Exome Variant Server (EVS; evs.gs.washing-
ton.edu/EVS), and Genome Aggregation Database (gnomAD gnomad.
broadinstitute.org/). TaggedEnd
TaggedH2 .4. Classification TaggedEnd
TaggedP en years ago, variants were classified following an in-house algo-
rithm including multiple parameters such as population frequencies, in
silico predictions, and published functional data. Algorithms followed
recommendations available in 2010 [11]. Part of this in-house algo-
rithm focused on inherited arrhythmogenic disorders was published in
2015 [12]. Nowadays, all variants have been reclassified according to
ACMG standards and guidelines for the interpretation of sequence var-
iants as P, LP, VUS, LB, or benign (B) [4]. The PM2 item in the ACMG
classification was considered fulfilled if Minor Allele Frequency (MAF)
in relevant population databases was 0.1% [13]. The vast majority of
reported pathogenic variants in IAS are extremely rare (<0.01%) [14].
High degree of pathogenicity (item PVS1) should only be used for rare
variants in genes where loss of function is a well-established disease
mechanism [15]. Genetic data were independently evaluated and clas-
sified by three clinical genetic experts. All investigators discussed and
agreed on a final classification of all variants to avoid bias.TaggedEnd
TaggedH13. Results TaggedEnd
TaggedH23.1. Cohort TaggedEnd
TaggedPOur retrospective study included 121 cases, all Caucasian, with an
even gender distribution (65 men; 53.71% and 56 women; 46.28%).
Ages ranged from 19 to 51 years of age (mean age: 39.2 years). The
first cohort (named “clinical group” CL-) included 104 cases (85.95%)
with a definite clinical diagnosis of IAS. Definitively, CL included 48
cases of BrS, 34 cases of ACM, 10 cases of LQTS, 7 cases of HCM, 4 cases
of CPVT, and only one case diagnosed with DCM (Fig. 1). Suspicious
cases with an inconclusive diagnosis were not included to avoid bias
in the reclassification of genetic variants. The second cohort (named
“post-mortem group” PM-) comprised 17 post-mortem samples
(14.05%) with IAS as the likely cause of death (Fig. 1). Exhaustive com-
plete autopsies were performed in all cases, including toxicological
analysis, before final judgment. Review of clinical and forensic data did
not change the diagnostic decisions from ten years ago.TaggedEnd
TaggedH23.2. Genetics TaggedEnd
TaggedPOne hundred twenty-eight rare variants were localized in 17
genes: 55 in SCN5A, 17 in PKP2, 9 in KCNH2 and RyR2, 8 in DSG2, 6 in
KCNQ1, 4 in MYBPC3, MYH7 and DSP, 3 in JUP, 2 in DSC2 and KCNE2,
and 1 in KCNE3, DES, LMNA and TGFB3. All identified variants were
exonic except one intronic variant (c.3840+1G>A_SCN5A, case 28). Of
the 127 exonic variants, 96 were missense and 31 were radical (tenTaggedEndTaggedP onsense, fifteen deletions and six insertions). All cases carried at
least one rare variant except for seven cases that carried two rare var-
iants (case 26, LQTS; case 28, BrS; case 65, BrS; case 72, LQTS; case 79,
ACM; case 107, ACM; and case 113, HCM). Original classification con-
cluded that there were 19 P variants (14.84%), 84 LP variants
(65.62%), 24 VUS variants (18.75%), and only one LB variant (0.78%)
(Fig. 1) (Tables 13).TaggedEnd
TaggedPReanalysis following current ACMG guidelines conferred signifi-
cant changes in 71.87% (92 of 128) of the rare variants. One variant
changed from LB to VUS (0.7%), 6 rare variants changed from VUS to
LB (4.6%), and one changed from VUS to LP (0.7%). Four rare variants
initially classified as LP in 2010 were changed to LB (3.1%), 59 were
changed to VUS (46.09%), and 10 were changed to P (7.8%). Ten rare
variants classified as P in 2010 were downgraded to LP in the reclassi-
fication (7.8%). In 2010, we classified 24 rare variants as VUS (18.75%)
and after reanalysis, there were 77 classified as VUS (60.15%; 17 rare
variants had no modification and 60 were reclassified). Originally,
the majority were LP variants (84 of 128; 65.62%), but after reanaly-
sis, the predominant classification of the variants was VUS (77 of
128; 60.65%) in contrast to 18.75% (24 of 128), ten years ago. Just
twenty-three of 128 (17.96%) were classified as LP. After reanalysis,
VUS became the predominant group (77 of 128; 60.65%) in contrast
to 18.75% (24 of 128) ten years ago. In 2010, only one variant (0.78%)
was classified as LB while after the reanalysis, 7.8% (10 of 128) were
classified LB. The percentage of P variants was similar in both classifi-
cations (19 of 128; 14.84% in 2010 and 18 of 128; 14.06% after the
reanalysis) (Fig. 2).TaggedEnd
TaggedPA total of 128 rare variants were analysed from 121 cases of IAS
(CL group). In 88 cases (82.72%), the variant classification suffered a
modification according to the current ACMG recommendations: 72 of
the 104 cases with an IAS diagnosis (69.23%) and 16 of the 17
(94.11%) cases from the post-mortem cohort. Originally, in the post-
mortem cohort, 82.23% (14 of 17) of variants were classified as LP,
while after the reanalysis the same percentage was classified as VUS
(14/17; 82.82%). In the IAS cohort, 63.06% (70 of 111) of the variants
were initially classified as LP. However, after the reanalysis, 56.75%
(63 of 111) were classified as VUS. Differences on the classification
were observed also between missense and radical variants. In the
2010 classification, 49 of the 79 missense variants (62.02%) were clas-
sified as LP, while the major classification after the reanalysis was
VUS (62 of 70; 78.48%). Radical variants were predominantly classi-
fied as LP in 2010 (21 of 31; 67.74%); although after the reanalysis a
58.06% of the radical variants were classified as P. The rare variants
located in five genes (DES, JUP, KCNE3, LMNA, and MYH7) did not suf-
fer any difference in final classification (Fig. 1) (Tables 3 and 4). TaggedEnd
T aggedPIn 48 cases of BrS, most rare variants were originally classified as
LP (41 of 49; 83.67%) but after reanalysis, most were classified as VUS
(34 of 49; 69.38%). In case number 28, diagnosed with BrS, an intronic
variant was originally classified as P but after reanalysis, was classi-
fied as LP. In ten cases diagnosed with LQTS, 50% (6 of 12 cases) were
classified as P but almost all rare variants have been reclassified as LP
(8 of 12; 66.66%). In four cases diagnosed with CPVT, all rare variants
(4 of 4; 100%) were originally classified as LP but after reanalysis, the
same four rare variants were classified as VUS. A total of 34 cases
diagnosed with ACM were originally classified as LP (52.77%; 19 of
36), but after reanalysis, most were classified as VUS (16 of 36;
44.44%). In the one case diagnosed with DCM, the rare variant origi-
nally classified as VUS remained at the same level of pathogenicity. In
seven cases diagnosed with HCM, 50% of rare variants were originally
classified as VUS (4 of 8) and after reanalysis, the same percentage of
VUS was maintained (Fig. 1) (Tables 1, 2 and 4).TaggedEnd
TaggedH14. Discussion TaggedEnd
TaggedPGenetic testing in patients diagnosed with IAS is highly recom-
mended both in clinical and medico-legal settings, since death is
TaggedEnd TaggedFigure
Fig. 1. Distribution of rare variants. White columns represent the original classification (2010). Black columns represent the classification after the reanalysis. (a) Global classifica-
tion of rare variants. (b) Global classification of rare missense variants. (c) Global classification of rare radical variants. (d) Classification of rare variants in Post-Mortem group. (e)
Classification of rare variants in Clinical group. (f) Classification of rare missense variants in Clinical group. (g) Classification of rare radical variants in Clinical group. TaggedEnd
TaggedEnd4 O. Campuzano et al. / EBioMedicine 54 (2020) 102732TaggedEndTaggedPoften the first manifestation of disease [3]. However, misinterpreta-
tion of rare variant designations may lead to inaccurate genetic diag-
noses and/or the adoption of unnecessary and/or inappropriateTaggedEndTaggedPtherapeutic approaches resulting in an increased morbidity and mor-
tality. Therefore, one of the main current challenges in genetic analy-
sis is determining the pathogenic role of rare variants. Identifying a
TaggedEnd Table 1
Variant genetic data.
Index case Disease Gene Nucleotide Protein dbSNP gnomAD HGMD (disease) ClinVar 2010 classification 2020 classification (ACMG)
1 BrS SCN5A c.5464_5467delTCTG p.(Glu1823Hisfs*10) rs794728924 1/249656 (0.0004%) CD077699 (SSS) P P P
2 ACM PKP2 c.1613G>A p.(Trp538*) rs193922672 4/251382 (0.001%) CM061177 (ACM) LP LP P
3 BrS SCN5A c.1717C>T p.(Gln573*) NA NA CM100660 (BrS) NA LP P
4 BrS SCN5A c.4477A>T p.(Lys1493*) NA NA CM100735 (BrS) NA LP P
5 BrS SCN5A c.2865_2866delGA p.(Glu955Aspfs*74) rs756159737 4/248468 (0.001%) NA NA LP LP
6 BrS SCN5A c.1721delG p.(Gly574Aspfs*49) NA NA CD100781 (BrS) NA LP LP
7 ACM DSG2 c.146G>A p.(Arg49His) rs121913006 1/249482 (0.0004%) CM061700 (ACM) LP VUS VUS
8 LQTS KCNQ1 c.421G>A p.(Val141Met) rs199472687 NA CM056972 (AF) LP P LP
9 BrS SCN5A c.4562T>A p.(Ile1521Lys) rs199473617 NA CM100736 (BrS) NA LP VUS
10 BrS SCN5A c.4534C>T p.(Arg1512Trp) rs137854602 14/251272 (0.005%) CM994138 (BrS) VUS LP VUS
11 BrS SCN5A c.5272_5274delATC p.(Ile1758del) NA NA CD1810427 (PCCD) NA LB VUS
12 BrS SCN5A c.707T>G p.(Leu236Arg) NA NA . NA LP VUS
13 ACM DSG2 c.1381C>T p.(Gln461*) rs1212557775 NA CM1314709 (ACM) NA LP LP
14 BrS SCN5A c.4978A>G p.(Ile1660Val) rs199473625 8/251490 (0.003%) CM057204 (LQTS) VUS LP VUS
15 BrS SCN5A c.2893C>T p.(Arg965Cys) rs199473180 16/246378 (0.006%) CM024644 (BrS) VUS LP VUS
16 ACM JUP c.1028G>A p.(Ser343Asn) NA NA NA NA VUS VUS
17 BrS SCN5A c.4352T>C p.(Val1451Ala) NA NA NA NA LP VUS
18 ACM JUP c.475G>T p.(Val159Leu) rs782702266 11/269700 (0.004%) CM1010258 (ACM) VUS VUS VUS
19 BrS SCN5A c.4493T>C p.(Met1498Thr) rs199473263 NA CM057203 (LQTS) VUS LP VUS
20 ACM DSP c.2956C>T p.(Gln986*) NA NA CM1310184 (ACM) NA LP P
21 ACM PKP2 c.2013delC p.Lys672Argfs*12 rs764817683 2/251350 (0.0007%) CD061457 (ACM) P P P
22 BrS SCN5A c.2550_2551dupGT p.Phe851Cysfs*19 rs397514450 NA CI055774 (DCM) P P P
23 BrS SCN5A c.4856delC p.Pro1619Argfs*12 NA NA CD100798 (BrS) NA LP P
24 BrS SCN5A c.1936del p.Gln646Argfs*5 rs727505158 1/31374 (0.003%) CD100782 (BrS) P LP P
25 BrS SCN5A c.5174C>T p.(Pro1725Leu) rs199473301 5/251170 (0.001%) CM097849 (LQTS) VUS LP VUS
26 LQTS KCNH2 c.2639G>T p.(Gly880Val) NA NA CM150041 (LQTS) NA P LP
KCNH2 c.1838C>T p.(Thr613Met) rs199473524 NA CM990761 (LQTS) P LP VUS
27 ACM PKP2 c.2203C>T p.(Arg735*) rs121434421 1/251356 (0.0003%) CM043061 (ACM) P P P
28 BrS SCN5A c.3840+1G>A NA NA NA CS099837 (BrS) NA P LP
SCN5A c.5068G>A p.(Asp1690Asn) rs1060499900 1/251488 (0.0003%) CM136071 (BrS) VUS LP VUS
29 BrS SCN5A c.2669T>C p.(Ile890Thr) NA NA CM130365 (BrS) NA LP VUS
30 BrS SCN5A c.1705dupC p.(Arg569Profs*152) NA NA CI1510495 (BrS) NA LP LP
31 BrS SCN5A c.1872dupA p.(Glu625Argfs*96) NA NA CI1510496 (BrS) NA LP LP
32 ACM PKP2 c.1912C>T p.(Gln638*) rs397517012 1/251302 (0.0003%) CM043056 (ACM) P P P
33 BrS SCN5A c.2729C>T p.(Ser910Leu) rs199473175 1/250430 (0.0003%) CM024643 (BrS) LP LP VUS
34 ACM PKP2 c.604dupG p.(Val202Glyfs*14) NA NA CI146422 (ACM) NA LP LP
35 ACM DSG2 c.137G>A p.(Arg46Gln) rs121913008 1/280866 (0.00003%) CM061701 (ACM) LP LP VUS
36 BrS SCN5A c.2962C>T p.(Arg988Trp) rs768691853 5/238498 (0.002%) CM137981 (BrS) VUS LP VUS
37 LQTS SCN5A c.5859_5862delTGAG p.(Ser1953Argfs*84) rs758317466 1/246198 (0.0004%) NA NA LP LP
38 BrS SCN5A c.4213G>A p.(Val1405Met) rs199473239 NA CM100715 (BrS) VUS P LP
39 BrS SCN5A c.361C>T p.(Arg121Trp) rs199473556 NA CM095355 (BrS) VUS LP VUS
40 BrS SCN5A c.1100G>A p.(Arg367His) rs28937318 NA CM020301 (SUNDS) LP P LP
41 BrS SCN5A c.5177C>G p.(Pro1726Arg) NA NA NA NA LP VUS
42 ACM TGFB3 c.1230A>C p.(Lys410Asn) NA NA NA NA LP VUS
43 ACM DSG2 c.2440T>C p.(Cys814Arg) NA NA CM146425 (ACM) NA LP VUS
44 ACM PKP2 c.275T>A p.(Leu92*) rs763639737 2/251424 (0.0007%) CM102825 (ACM) P P P
45 ACM DES c.407T>A p.(Leu136His) rs397516695 15/213206 (0.007%) CM159728 (DCM) VUS VUS VUS
46 ACM DSP c.6208G>A p.(Asp2070Asn) rs41302885 1118/282114 (0.39%) CM198079 (BrS) LB VUS LB
47 LQTS KCNQ1 c.898G>A p.(Ala300Thr) rs120074187 12/249914 (0.004%) CM983511 (LQTS) VUS P LP
48 BrS SCN5A c.2548G>A p.(Val850Met) rs911293694 2/251416 (0.0007%) NA NA LP VUS
49 BrS SCN5A c.5380T>A p.(Phe1794Ile) NA NA NA NA LP VUS
50 BrS SCN5A c.4018G>A p.(Val1340Ile) rs199473605 13/ 282822 (0.004%) CM100703 (BrS) VUS LP VUS
51 HCM MYH7 c.5779A>T p.(Ile1927Phe) rs767300277 11/251320 (0.004%) CM082963 (HCM) VUS VUS VUS
52 BrS SCN5A c.2168dupT p.(Thr724Hisfs*21) NA NA NA NA LP LP
(continued on next page)
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Table 1 (Continued)
Index case Disease Gene Nucleotide Protein dbSNP gnomAD HGMD (disease) ClinVar 2010 classification 2020 classification (ACMG)
53 BrS SCN5A c.2314G>A p.(Asp772Asn) rs199473157 5/249248 (0.002%) CM097652 (LQTS) VUS LP VUS
54 BrS SCN5A c.4219dupG p.(Ala1407Glyfs*13) NA NA NA NA LP P
55 ACM DSG2 c.473T>G p.(Val158Gly) rs191143292 1537/280564 (0.54%) CM070921 (ACM) LB VUS LB
56 BrS SCN5A c.1577G>A p.(Arg526His) rs45627438 14/242632 (0.005%) CM100657 (BrS) VUS LP VUS
57 BrS SCN5A c.1120T>C p.(Trp374Arg) NA NA NA NA LP VUS
58 LQTS KCNQ1 c.1016T>C p.(Phe339Ser) rs199472759 NA CM073160 (LQTS) LP P LP
59 ACM PKP2 c.1162C>T p.(Arg388Trp) rs766209297 1/251320 (0.0003%) CM097906 (ACM) LP LP VUS
60 BrS SCN5A c.4345T>C p.(Tyr1449His) NA NA NA NA VUS VUS
61 BrS SCN5A c.481G>A p.(Glu161Lys) rs199473062 1/240992 (0.0004%) CM023671 (BrS) LP VUS VUS
62 ACM DSG2 c.166G>A p.(Val56Met) rs121913013 518/280886 (0.18%) CM070918 (ACM) LB VUS LB
63 ACM PKP2 c.1378G>A p.(Asp460Asn) rs794729106 NA CM1213407 (ACM) NA P LP
64 ACM DSP c.6361G>C p.(Gly2121Arg) rs368227724 1/251360 (0.0003%) NA NA LP VUS
65 BrS SCN5A c.1579G>C p.(Gly527Arg) rs763550164 8/243942 (0.003%) NA VUS LP VUS
SCN5A c.3929C>G p.(Pro1310Arg) NA NA NA NA LP VUS
66 BrS SCN5A c.2236G>A p.(Glu746Lys) rs199473582 5/248406 (0.002%) CM100669 (BrS) VUS LP VUS
67 CPVT RYR2 c.14639T>C p.(Val4880Ala) rs1242723821 NA HM030023 (CPVT) NA LP VUS
68 ACM PKP2 c.2576delA p.(Lys859Argfs*72) NA NA CD146431 (ACM) NA LP LP
69 ACM PKP2 c.1643delG p.(Gly548Valfs*15) rs794729137 NA CD043194 (ACM) P P P
70 BrS SCN5A c.2633G>A p.(Arg878His) rs199473587 NA CM100676 (BrS) NA LP VUS
71 ACM PKP2 c.2060T>G p.(Leu687Arg) rs794729113 NA NA VUS VUS VUS
72 LQTS KCNH2 c.712G>C p.(Gly238Arg) NA NA NA NA VUS VUS
KCNQ1 c.944A>G p.(Tyr315Cys) rs74462309 NA CM981127 (LQTS) LP VUS LP
73 BrS SCN5A c.5859_5862delTGAG p.(Ser1953Argfs*84) rs758317466 1/246198 (0.0004%) NA NA LP LP
74 ACM PKP2 c.1759G>A p.(Val587Ile) rs146102241 616/251180 (0.24%) NA LB VUS LB
75 BrS SCN5A c.4981G>A p.(Gly1661Arg) NA NA CM100750 (BrS) NA LP VUS
76 ACM DSG2 c.527C>T p.(Thr176Ile) rs536617217 4/280698 (0.001%) NA VUS LP VUS
77 LQTS KCNH2 c.1744C>T p.(Arg582Cys) rs121912508 NA CM990759 (LQTS) P P LP
78 BrS SCN5A c.5177C>A p.(Pro1726His) NA NA NA NA LP VUS
79 ACM DSC2 c.835C>T p.(Arg279Cys) rs193922708 12/251360 (0.004%) CM146543 (ACM) VUS LP LP
PKP2 c.1882delC p.(Gln628Argfs*28) NA NA CD146544 (ACM) NA LP VUS
80 BrS SCN5A c.4052T>G p.(Met1351Arg) rs199473232 NA CM100707 (BrS) NA LP VUS
81 BrS SCN5A c.5092G>A p.(Ala1698Thr) rs199473295 3/251490 (0.001%) CM100753 (BrS) VUS VUS VUS
82 SCD RYR2 c.2047G>A p.(Glu683Lys) NA NA NA NA LP VUS
83 SCD RYR2 c.12056T>C p.(Met4019Thr) rs886039150 NA CM173280 (MI) VUS LP VUS
84 SCD KCNE2 c.29C>T p.(Thr10Met) rs199473648 66/282722 (0.023%) CM055291 (LQTS) VUS VUS LB
85 SCD KCNH2 c.2674C>T p.(Arg892Cys) rs201627778 111/277590 (0.039%) CM1413446 (SCD) VUS LP VUS
86 SCD RYR2 c.12919C>T p.(Arg4307Cys) rs200092869 86/248746 (0.03%) NA VUS LP VUS
87 SCD KCNE1 c.253G>A p.(Asp85Asn) rs1805128 2637/282814 (0.9%) CM040436 (LQTS, DI) B LP LB
88 BrS SCN5A c.3911C>T p.(Thr1304Met) rs199473603 46/279030 (0.01%) CM992663 (LQTS) VUS LP VUS
89 SCD SCN5A c.1440A>C p.(Lys480Asn) rs752966781 2/249180 (0.0008%) NA VUS LP VUS
90 CPVT RYR2 c.14667C>G p.(Phe4889Leu) NA NA NA NA LP VUS
91 HCM MYBPC3 c.2827C>T p.(Arg943*) rs387907267 3/247124 (0.001%) CM032959 (HCM) P LP P
92 SCD RYR2 c.8145G>T p.(Glu2715Asp) rs200420897 14/134624 (0.01%) NA VUS LP VUS
93 SCD KCNH2 c.865G>A p.(Glu289Lys) rs199472880 7/35014 (0.01%) CM097827 (LQTS) VUS LP VUS
94 SCD KCNH2 c.2860C>T p.(Arg954Cys) rs141401803 8/217960 (0.003%) CM070176 (SIDS) VUS LP VUS
95 SCD SCN5A c.3530C>G p.(Pro1177Arg) NA NA NA NA LP VUS
96 LQTS KCNQ1 c.1097G>A p.(Arg366Gln) rs199473410 1/251240 (0.0003%) CM002330 (LQTS) P P LP
97 SCD SCN5A c.5054_5055delinsTT p.(Glu1685Val) NA NA NA NA LP VUS
98 ACM JUP c.2069A>G p.(Asn690Ser) rs147628503 29/282402 (0.01%) CM1416877 (Autism) VUS VUS VUS
99 HCM MYBPC3 c.3328delA p.(Met1110Trpfs*79) NA NA CD1710421 (HCM) NA LP P
100 SCD KCNH2 c.2941A>G p.(Ser981Gly) rs76649554 75/276264 (0.027%) NA VUS LP VUS
101 HCM MYH7 c.4377G>C p.(Lys1459Asn) rs201307101 NA CM042424 (HCM) NA VUS VUS
102 CPVT RYR2 c.217C>G p.(Leu73Val) rs777753947 1/249224 (0.0004%) CM1413452 (SCD) NA LP VUS
103 LQTS KCNQ1 c.1861G>A p.(Gly621Ser) rs199472820 9/177000 (0.005%) CM1413447 (SCD) VUS LP VUS
104 ACM PKP2 c.1130T>C p.(Ile377Thr) rs397516985 1/31416 (0.003%) NA VUS LP VUS
(continued on next page)
TaggedEnd6
O
.Cam
puzano
etal./EBioM
edicine
54
(2020)
102732
Ta
bl
e
1
(C
on
ti
nu
ed
)
In
de
x
ca
se
D
is
ea
se
G
en
e
N
uc
le
ot
id
e
Pr
ot
ei
n
db
SN
P
gn
om
A
D
H
G
M
D
(d
is
ea
se
)
Cl
in
V
ar
20
10
cl
as
si
fi
ca
ti
on
20
20
cl
as
si
fi
ca
ti
on
(A
CM
G
)
10
5
SC
D
SC
N
5A
c.
28
7T
>
C
p.
(L
eu
96
Pr
o)
N
A
N
A
N
A
N
A
LP
V
U
S
10
6
A
CM
PK
P2
c.
76
G
>
A
p.
(A
sp
26
A
sn
)
rs
14
30
04
80
8
14
27
/1
68
71
0
(0
.8
%)
CM
06
11
72
(A
CM
)
LB
LP
LB
10
7
A
CM
D
SG
2
c.
90
8C
>
T
p.
(S
er
30
3P
he
)
rs
75
77
92
71
4
2/
24
94
00
(0
.0
00
8%
)
CM
16
16
31
8
(A
CM
)
V
U
S
LP
V
U
S
D
SC
2
c.
90
7G
>
A
p.
(V
al
30
3M
et
)
rs
14
55
60
67
8
28
2/
28
28
24
(0
.0
9%
)
CM
11
72
22
(D
CM
)
LB
LP
V
U
S
10
8
SC
D
K
CN
E3
c.
24
8G
>
A
p.
(A
rg
83
H
is
)
rs
17
21
54
37
85
9/
28
26
68
(0
.3
%)
CM
01
17
95
(P
P)
LB
V
U
S
V
U
S
10
9
CP
V
T
RY
R2
c.
12
41
9G
>
A
p.
(G
ly
41
40
G
lu
)
N
A
N
A
N
A
N
A
LP
V
U
S
11
0
A
CM
PK
P2
c.
25
3_
25
6d
el
G
A
G
T
p.
(G
lu
85
M
et
fs
*2
6)
rs
78
62
04
38
8
1/
25
14
10
(0
.0
00
3%
)
CD
10
28
29
(A
CM
)
P
P
P
11
1
Br
S
SC
N
5A
c.
29
24
G
>
C
p.
(A
rg
97
5P
ro
)
N
A
N
A
N
A
N
A
LP
V
U
S
11
2
SC
D
RY
R2
c.
72
01
C>
T
p.
(A
rg
24
01
Cy
s)
rs
13
21
28
31
06
2/
31
39
8
(0
.0
06
%)
N
A
N
A
LP
V
U
S
11
3
H
CM
M
YB
PC
3
c.
15
13
_1
51
5d
el
A
A
G
p.
(L
ys
50
5d
el
)
rs
72
75
04
28
7
2/
24
92
64
(0
.0
00
8%
)
CD
03
15
19
(H
CM
)
N
A
P
LP
M
YB
PC
3
c.
56
5G
>
A
p.
(V
al
18
9I
le
)
rs
11
57
00
52
63
7/
24
51
40
(0
.2
5%
)
CM
16
91
51
(H
CM
)
LB
LP
LB
11
4
Br
S
SC
N
5A
c.
10
97
T>
C
p.
(P
he
36
6S
er
)
N
A
N
A
N
A
N
A
LP
V
U
S
11
5
H
CM
M
YH
7
c.
51
17
T>
C
p.
(L
eu
17
06
Pr
o)
rs
79
70
44
60
2
N
A
CM
04
24
28
(M
yo
pa
th
y)
LP
V
U
S
V
U
S
11
6
H
CM
M
YH
7
c.
48
65
T>
C
p.
(L
eu
16
22
Pr
o)
N
A
N
A
N
A
N
A
V
U
S
V
U
S
11
7
SC
D
K
CN
E2
c.
22
A
>
G
p.
(T
hr
8A
la
)
rs
22
34
91
6
10
59
/2
82
72
0
(0
.3
7%
)
CM
00
34
49
(L
Q
TS
,D
I)
LB
V
U
S
LB
11
8
A
CM
D
SP
c.
88
G
>
A
p.
(V
al
30
M
et
)
rs
12
19
12
99
8
35
8/
23
95
38
(0
.1
4%
)
CM
06
39
61
(A
CM
)
LB
LP
LB
11
9
A
CM
PK
P2
c.
17
5C
>
T
p.
(G
ln
59
*)
N
A
N
A
CM
13
13
04
1
(A
CM
)
N
A
LP
P
12
0
D
CM
LM
N
A
c.
10
56
G
>
T
p.
(M
et
35
2I
le
)
N
A
N
A
N
A
N
A
V
U
S
V
U
S
12
1
LQ
TS
K
CN
H
2
c.
98
2C
>
G
p.
(A
rg
32
8G
ly
)
rs
19
94
73
50
5
16
1/
28
22
46
(0
.0
57
%)
N
A
V
U
S
V
U
S
V
U
S
N
ot
e

A
CM
:a
rr
hy
th
m
og
en
ic
ca
rd
io
m
yo
pa
th
y,
A
F:
at
ri
al
fi
br
ill
at
io
n,
A
CM
G
:A
m
er
ic
an
Co
lle
ge
of
M
ed
ic
al
G
en
et
ic
s
an
d
G
en
om
ic
s,
B:
be
ni
gn
,B
rS
:B
ru
ga
da
sy
nd
ro
m
e,
Cl
in
V
ar
:c
lin
ic
al
va
ri
at
io
n,
CP
V
T:
ca
te
ch
ol
am
in
er
gi
c
po
ly
m
or
-
ph
ic
ve
nt
ri
cu
la
r
ta
ch
yc
ar
di
a,
D
CM
:d
ila
te
d
ca
rd
io
m
yo
pa
th
y,
D
M
:d
is
ea
se
m
ut
at
io
n,
gn
om
A
D
:g
en
om
e
ag
gr
eg
at
io
n
da
ta
ba
se
,H
CM
:h
yp
er
tr
op
hi
c
ca
rd
io
m
yo
pa
th
y,
H
G
M
D
:h
um
an
ge
no
m
e
m
ut
at
io
n
da
ta
ba
se
,L
B:
lik
el
y
be
ni
gn
,L
P:
lik
el
y
pa
th
og
en
ic
,L
Q
TS
:l
on
g
Q
T
sy
nd
ro
m
e,
LQ
TS
-D
I:
lo
ng
Q
T
sy
nd
ro
m
e
dr
ug
-i
nd
uc
ed
,M
I:
m
yo
ca
rd
ia
li
nf
ar
ct
io
n,
N
A
:n
ot
av
ai
la
bl
e
da
ta
,P
:p
at
ho
ge
ni
c,
PC
CD
:p
ro
gr
es
si
ve
ca
rd
ia
c
co
nd
uc
ti
on
di
se
as
e,
PP
:p
er
io
di
c
pa
ra
ly
si
s,
SC
D
:
su
dd
en
ca
rd
ia
c
de
at
h,
SI
D
S:
su
dd
en
in
fa
nt
de
at
h
sy
nd
ro
m
e,
SS
S:
si
ck
si
nu
s
sy
nd
ro
m
e,
SU
N
D
S:
su
dd
en
un
ex
pe
ct
ed
de
at
h
sy
nd
ro
m
e,
V
U
S:
va
ri
an
to
fu
nc
er
ta
in
si
gn
ifi
ca
nc
e.
TaggedEndO. Campuzano et al. / EBioMedicine 54 (2020) 102732 7TaggedEndTaggedP enetic cause of IAS allows for accurate clinical diagnosis, risk stratifi-
cation, adoption of personalized therapeutic measures, and early
identification of relatives at risk, while also determining no genetic
carriers [16]. Obtaining reliable and accountable interpretations of
variant significance is as important as improving molecular diagnos-
tic techniques, and for these reason adequate guidelines, and also a
periodic update of the criteria used for interpretation and revision of
the variant significances, are fundamental. TaggedEnd
TaggedPIn our retrospective study, we have applied current ACMG recom-
mendations for variant classification in a cohort of patients diagnosed
with IAS and post-mortem cases with suspected IAS [4]. We deter-
mined that over 70% of variants required reclassification after ten
years under the updated guidelines. Specifically, after reanalysis of
the variants, 69.23% of diagnosed IAS cases required a change in vari-
ant classification. In the post-mortem cohort, 94.11% required a
change in variant classification. This data reinforces the need for clini-
cal data in genetic diagnoses; a complete clinical history contributes
to variant classification and helps to clarify the role of a variant in
each patient. Recently, a study focused on the reclassification of VUS
in IAS concluded that disease-specific phenotypes significantly
increase the accuracy of classification [10]. Interestingly, we deter-
mined that many missense variants changed their classification from
LP to VUS after reanalysis; this modification is mainly due to the
increase of items used in ACMG recommendations. As mentioned
above, increase in items implies more accuracy in classification but
also stringency. In contrast, many radical variants changed from LP to
P, accordingly to Harrison et al. [17] This fact suggests that variants
resulting in a premature truncation of proteins and/or frameshifts
should be considered highly damaging and therefore should be care-
fully analysed. Missense variants should be comprehensively ana-
lysed in each patient, considering all available data to perform a
proper variant prioritization in a personalized clinical context [18].
Family segregation is the most robust tool to corroborate the patho-
genic role of a particular variant. Unfortunately, a complete segrega-
tion for most rare variants currently associated with IAS is not
available. In addition, incomplete penetrance/variable expressivity
are hallmarks of IAS, so a segregation analysis of at least three gener-
ations should be recommended to obtain helpful data [19, 20]. Thus,
the disease manifestation observed at the basal assessment and the
clinical evolution on the follow-up, not only in the index cases but in
the entire families, may also be highly useful in the understanding of
the pathogenic role of the initially identified variants. Despite all the
previously mentioned considerations, the frequency of rare variants
in the global population is the first tool used to help to discern a
potential damaging variant from other rare variants with no potential
deleterious role. Nowadays, free and quick access to on-line data-
bases focused on variant population frequencies makes this an easy
routine approach.TaggedEnd
TaggedPClassification of a variant as VUS or downgrading a variant status
from LP to VUS does not mean that there is less pathogenic risk of IAS
for any patient who carries the rare variant; ambiguous significance
implies that current evidence does not back a conclusive deleterious
role in IAS. Therefore, clinical translation of VUS should be performed
with caution and VUS should not be discarded, at least until addi-
tional data becomes available focused on clarifying their clinical role.
Current recommendations for the interpretation of rare variants [4]
include more items to be considered than ten years ago [11]. This
increase in items implies more accuracy in classification but also
increased stringency; thus, a lack of data for some of these items
leads to ambiguous classification [5]. As a consequence, a low per-
centage of variants classified currently as VUS confer a real of risk in
IAS and most are LB [21]. To discriminate a true risk-carrying variant
from a non-deleterious variant is a challenge without accurate family
segregation and functional studies [7]. Expected frequencies of each
IAS variant and constant update of minor allele frequencies in large
global population studies should be used to help identify the genes,
TaggedEnd Table 2
Modifications in classification of rare variant.
Total Total of
Changes
PM Changes
in PM
CL Changes
in CL
Rare Variants 128 92 (71,87%) 17 16 (94,11%) 111 76 (68,46%)
Cases 121 88 (72,72%) 17 16 (94,11%) 104 72 (69,28%)
Note  CL: clinical group, PM: post-mortem group.
TaggedEnd TaggedFigure
Fig. 2. Reclassification of rare variants. White colour represents the number of rare
variants classified as LB. Soft grey colour represents the number of rare variants classi-
fied as VUS. Dark grey colour represents the number of rare variants classified as LP.
Black colour represents the number of rare variants classified as P. Concrete number of
variants is included inside each part. TaggedEnd
TaggedEnd8 O. Campuzano et al. / EBioMedicine 54 (2020) 102732TaggedEndTaggedPregions of genes, and/or types of variants strongly associated with IAS
which may help to determine the roles of variants in clinical settings,
particularly if they are classified as VUS [22].TaggedEnd
TaggedPAt the present time, while the ACMG recommend how to classify
variants, there is currently no consensus for when and how often var-
iants should be reclassified. Therefore, reinterpretation of genetic
variants occurs mainly due to a clinician’s request, identification of a
previously classified variant in a new patient or new data available
concerning the rare variant [23]. These expectations should be explic-
itly delineated as part of the informed consent process before the
sample is obtained and reviewed again when disclosing initial results
[24]. Concerning IAS, Smith et al. reported a reclassification after one
year of 3% of rare variants [25]. In 2018, a reclassification of rare var-
iants previously considered deleterious in Brugada Syndrome was
performed; only 37% were classified as P or LP following current
ACMG recommendations [8]. A recent study identified a modification
in 52% of rare variants classified as VUS seven years ago [10]. There-
fore, the evidence supports the periodic reclassification of the rare
variants in IAS despite lack of data concerning the time of re-evalua-
tion. In our report, more than 70% of rare variants were reclassified
after ten years, also supporting the necessity of re-evaluation. In the
light of all this evidence, we propose that rare variants associated
with IAS should be reanalysed within five years if already classified
following ACMG recommendations since it seems to be adequate to
manage the rapid obsolescence of genetic data interpretations. In
addition, our results support further urgent reanalysis of each IAS
rare variant if they were not classified originally following ACMG rec-
ommendations. TaggedEnd
TaggedP he next step should be clinical translation of the re-evaluation
and assessment of the implications in families because the confirma-
tion of a variant as P, or removal of a P designation, may have a signif-
icant impact on patients and relatives. Therapeutic management canTaggedEnd able 3
Classification of rare variants in each gene.
2010
Genes Number variants LB VUS LP P
DES 1 . 1 . .
DSC2 2 . . 2 .
DSG2 8 . 3 5 .
DSP 4 . 1 3 .
JUP 3 . 3 . .
KCNE1 1 . . 1 .
KCNE2 2 . 2 . .
KCNE3 1 . 1 . .
KCNH2 9 . 2 5 2
KCNQ1 6 . 1 1 4
LMNA 1 . 1 . .
MYBPC3 4 . . 3 1
MYH7 4 . 4 . .
PKP2 17 . 2 8 7
RYR2 9 . . 9 .
SCN5A 55 1 3 46 5
TGFB3 1 . . 1 .
TOTAL 17 128 1 24 84 19
Note  LB: likely benign, LP: likely pathogenic, P: pathogenic, VUS: variant of uncertain signifiTaggedEndTaggedPbe modified but emotional and psychological impacts may have last-
ing effects [26]. New genetic information can lend itself to misinter-
pretation [5], so we recommended discussions with an expert
cardiologist in genetics to explain what reclassification entails for
each patient, accordingly to recent American Society of Human
Genetics recommendations (ASHG) [27]. One key point is that a
change in classification does not necessarily change the fact that a
case has an IAS. Finally, it is important to remark that our re-informa-
tion approach to families follows the ethical premise that definitive
consideration for any clinical or research guideline should be improv-
ing patient medical care. TaggedEnd
TaggedPWe can highlight some major limitations to our study. Variant
interpretation is subject to inherent intra- and inter-laboratory dif-
ferences in data interpretation [28]. In the current study, three of the
authors performed independent classification following ACMG rec-
ommendations and all authors came to a consensus regarding the
final classification decision. All rare variants were identified after a2020
LB VUS LP P Modification 2010 vs. 2020
. 1 . . NO
. 2 . . YES
2 5 1 . YES
2 1 . 1 YES
. 3 . . NO
1 . . . YES
2 . . . YES
. 1 . . NO
. 7 2 . YES
. 1 5 . YES
. 1 . . NO
1 . 1 2 YES
. 4 . . NO
2 3 4 8 YES
. 9 . . YES
. 38 10 7 YES
. 1 . . YES
10 77 23 18
cance.
TaggedEnd Table 4
Classification of rare variants in IAS subtypes.
All Missense Radical
Disease Number Variants 2010 2020 2010 2020 2010 2020
BrS 49 LB 1 . . . 1 .
VUS 3 34 3 33 . 1
LP 41 8 30 2 11 6
P 4 7 2 0 2 7
LQTS 12 LB . . . . . .
VUS 3 4 3 4 . .
LP 3 8 2 7 1 1
P 6 . 6 . . .
CPVT 4 LB . . . . . .
VUS . 4 . 4 . .
LP 4 . 4 . . .
P . . . . . .
ACM 36 LB . 6 . 6 . .
VUS 10 16 10 16 . .
LP 19 5 12 1 7 4
P 7 9 1 . 6 9
DCM 1 LB . . . . . .
VUS 1 1 1 1 . .
LP . . . . . .
P . . . . . .
HCM 8 LB . 1 . 1 . .
VUS 4 4 4 4 . .
LP 3 1 1 . 2 1
P 1 2 . . 1 2
Note  ACM: arrhythmogenic cardiomyopathy, BrS: Brugada syndrome, CPVT: cate-
cholaminergic polymorphic ventricular tachycardia, DCM: dilated cardiomyopathy,
HCM: hypertrophic cardiomyopathy, LB: likely benign, LQTS: long QT syndrome, LP:
likely pathogenic, P: pathogenic, VUS: variant of uncertain significance.
TaggedEndO. Campuzano et al. / EBioMedicine 54 (2020) 102732 9TaggedEndTaggedPlimited analysis of genes; we cannot be sure that patients do not
carry other rare variants in genes currently unassociated with IAS.
Only genes currently associated with IAS were analysed. The number
of cases analysed was small, so comprehensive reassessment should
be performed in large cohorts of IAS samples to corroborate a peri-
odic reclassification. Finally, lack of data for some of the rare variants,
mainly concerning functional studies as well as familial segregation,
impedes comprehensive interpretation of our results and definite
classification. TaggedEnd
TaggedPIn summary, reanalysis using current ACMG recommendations
showed that 71.87% of rare variants in IAS were given a new classifi-
cation than originally assigned ten years ago. Many variants, how-
ever, remain of ambiguous significance. These findings emphasize
the importance of cautious interpretation of variant scoring and com-
prehensive family segregation, supporting the periodic re-evaluation
of rare variants in IAS before clinical translation. It is extremely
important that in cases of significance changes after an update the
geneticist promptly informs the interested patients. TaggedEndTaggedH1Declaration of Competing Interest TaggedEnd
TaggedP he authors have no conflicts of interest to declare. TaggedEndTaggedH1Funding sources/Acknowledgments TaggedEnd
TaggedP his work was supported by Obra Social "La Caixa Foundation" (ID
100010434, LCF/PR/GN16/50290001 and LCF/PR/GN19/50320002),
Fondo Investigacion Sanitaria (FIS PI16/01203 and FIS, PI17/01690)
from Instituto Salud Carlos III (ISCIII), Sociedad Espa~nola de Cardiolo-
gía (Proyecto Investigacion Basica Cardiología 2015 de los Socios
Estrategicos SEC), and “Fundacio Privada Daniel Bravo Andreu”.
CIBERCV is an initiative of the ISCIII, Spanish Ministry of Economy
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